Search results
Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?
Investor's Business Daily· 1 hour agoModerna stock is yo-yoing after the company unveiled early-stage test results for its...
Will Higher Keytruda Sales Drive Merck's Q1
Forbes· 15 hours agoMerck (NYSE: MRK) will report its Q1 2024 results on Thursday, April 25. As usual, Keytruda will be the driving growth for Merck with quarterly sales...
Why Australian Cancer Biotech Firm Immutep Stock Is Soaring On Wednesday?
Benzinga via Yahoo Finance· 3 hours agoThe investigational immuno-oncology combination demonstrates an overall response rate (ORR) of...
Immutep Announces Positive Preliminary Topline Results from TACTI-003 Cohort B
Morningstar· 8 hours agoMedia Release Data from efti in combination with KEYTRUDA® in first line head and neck squamous cell carcinoma patients who do not express PD-L1 (TACTI-003, Cohort B) shows ...
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 in...
WTNH-TV New Haven· 19 hours agoUpon the execution of the agreement, Hanmi Pharmaceutical will conduct a phase 1 clinical trial to...
Merck Earnings Preview: Strong quarter expectations on the back of core products' growth
Seeking Alpha· 6 hours agoMerck (NYSE:MRK) is scheduled to announce Q1 earnings results on Thursday, April 25th, before market...
4 Large Drug Stocks to Hold on to Amid Industry Challenges
Zacks via Yahoo Finance· 6 hours agoDrug and biotech companies are likely to see significant innovation. In the Large-Cap...
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
Zacks via Yahoo Finance· 2 days agoInvestor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda...
What's in Store for These 5 Pharma Bigwigs in Q1 Earnings?
Zacks via Yahoo Finance· 7 hours agoStrong global underlying demand across Merck’s business, particularly for cancer drug Keytruda and...
...Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in...
Morningstar· 1 day agoThe VERSATILE-002 trial is evaluating Versamune® HPV (formerly PDS0101) in combination with the immune checkpoint...
